<FORM>
References                                                                                                                 I
Appendices                                                                                                            XXVI
         Appendix   A: Resolution WHA70.12                                                                           XXVIII
         Appendix   B: Five-year age standardized   survival rates for cancers                                       XXXIII
         Appendix   C: Members   of informal  advisory groups                                                       XXXVIII
         Appendix   D: List of key publications relating to reviews of medicine pricing                                  XL
         Appendix   E: Health expenditure  on  pharmaceuticals  and  disease  burden                                    XLI
</FORM>
<TEXT>
Fig. 1.1: Year-on-year growth rates of expenditures on cancer medicines and health care ..................................................... 3 Fig. 1.2: Comparison of expenditures on cancer medicines and health based on per-capita expenditures, by (a) incident cases and (b) prevalent cases......................................................................................................................................4 Fig. 1.3: Points along the value chain and product life-cycles for price setting and management ......................................... 6 Fig. 3.1: Cost structure of pharmaceutical and life science industry, by company type and year ........................................ 20 Fig. 3.2: Timeline of price planning activities for palbociclib ........................................................................................................... 22 Fig. 3.3: Timeline of price planning activities for sofosbuvir ............................................................................................................ 23 Fig. 3.4: Threshold analysis of revenue return, by R&D expenses and years since product launch .................................... 25 Fig. 3.5: Cumulative sales incomes of cancer medicines in 2017 US dollars, by molecule ..................................................... 26 Fig. 3.6: Distribution of market share by 2017 sales value and Herfindahl-Hirschman Index ................................................ 28 Fig. 3.7: Comparison of factors of profit ................................................................................................................................................. 31 Fig. 3.8: Dimensions that may be considered for determining the value of medicines .......................................................... 34 Fig. 3.9: External reference pricing, by country and country GDP-per-capita ranking ............................................................ 37 Fig. 3.10: Types of MEA applied for cancer medicines in European countries ........................................................................... 42 Fig. 4.1: Comparative expenditure on cancer medicine in (a) Australia and (b) Norway ........................................................ 54 Fig. 4.2: Comparative expenditure on high-cost specialty medicine in the USA....................................................................... 55 Fig. 4.3: Median prices of EML cancer medicines, by country income and cancer incidence ............................................... 57 Fig. 4.4: Cumulative percentage change from baseline mean monthly cost in the USA, by year ....................................... 58 Fig. 4.5: Costs of cancer medicines (a) without and (b) with adjustment for purchasing power .......................................... 60 Fig. 4.6: Cumulative real pharmaceutical price inflation in (a) Australia and US with year 1981 as the baseline year (b) Australia, US and Euro area with year 2000 as the baseline year ................................................................................... 61 Fig. 4.7: Australian Government’s reimbursement for cancer medicines dispensed (2011–2016) ......................................... 63 Fig. 4.8: Availability of cancer medicines in national formularies of non-European countries in 2016, by country ranked by GDP per capita in 2016 ........................................................................................................................................... 69 Fig. 4.9: Availability of cancer medicines in national formularies of European countries in 2014, by country ranked by GDP per capita in 2016 ............................................................................................................................................................... 70 Fig. 4.10: Decision outcomes on the coverage of cancer medicines (2002–2014) in 10 European countries or areas .. 72
</TEXT>
<PAGE_BREAK>
